TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8912126

Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (TBS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sucralfate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aluminium hydroxide
Number of subjects: 30
Study: 1714018

Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms)
Number of subjects: 8
Study: 7128190

Group type: EXPERIMENTAL
Intervention: Benzydamine oral rinse
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo oral rinse
Number of subjects: 52
Study: 31442785

Group type: EXPERIMENTAL
Intervention: 12-week home-based brisk walking program
Number of subjects: 159

Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 159
Study: 29940255

Group type: EXPERIMENTAL
Intervention: Cortisol suppression at encoding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no cortisol suppression)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortisol levels
Number of subjects: 0
Study: 23981567

Group type: COMPARATOR
Intervention: Aquatic treadmill (ATM) running
Number of subjects: 12
Study: 23145517

Group type: EXPERIMENTAL
Intervention: Computer-based simulation activities
Number of subjects: 58

Group type: COMPARATOR
Intervention: Laboratory-based simulation activities
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Non-English first-language students
Number of subjects: 58
Study: 20235087

Group type: EXPERIMENTAL
Intervention: Preoperative oral carbohydrate loading; 61.0% compliance in audit group vs 96% in trial group; P < 0.001
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Transverse incision; 25.0% in audit group vs 39% in trial group; P = 0.037
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Early fluid and diet reintroduction; 73.0% in audit group vs 99% in trial group; P < 0.001
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Non-opiate postoperative oral analgesia; 70.0% in audit group vs 99% in trial group; P < 0.001
Number of subjects: 195

Group type: COMPARATOR
Intervention: Length of hospital stay; median 7 days (audit group) vs 6 days (trial group); no significant difference
Number of subjects: 195

Group type: COMPARATOR
Intervention: Septic morbidity; not available
Number of subjects: 195

Group type: COMPARATOR
Intervention: 30-day mortality rates; not available
Number of subjects: 195
Study: 18617752

Group type: EXPERIMENTAL
Intervention: Anterior vitrectomy (group A, 19 eyes)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Posterior optic capture without vitrectomy (group B, 21 eyes)
Number of subjects: 40
Study: 16091636

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control (no lisinopril)
Number of subjects: 94
Study: 12519102

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) at a final dose of 900-2100 mg for 14 days, followed by 7 days without OXC, then 14 days back on OXC.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) during the on-periods.
Number of subjects: 12
Study: 11979208

Group type: EXPERIMENTAL
Intervention: Evidence-based intervention protocols for nurse-led continence service
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse-led continence service
Number of subjects: 0
Study: 9604993

Group type: EXPERIMENTAL
Intervention: IL-2 secreting helper T lymphocyte precursors (HTLp) frequency testing
Number of subjects: 58

Group type: COMPARATOR
Intervention: Cytotoxic T lymphocyte precursors (CTLp) frequency testing
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Combined testing of HTLp and CTLp frequencies
Number of subjects: 58
Study: 7544207

Group type: EXPERIMENTAL
Intervention: Microwave hyperthermia for 1 hour
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Microwave hyperthermia
Number of subjects: 96
Study: 2666475

Group type: EXPERIMENTAL
Intervention: Self-paced learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulant therapy
Number of subjects: 0
Study: 344019

Group type: EXPERIMENTAL
Intervention: M‐‐M (decreasing daily dose of methadone in two equal doses given 12 hours apart)
Number of subjects: 22

Group type: COMPARATOR
Intervention: M‐‐PN (decreasing daily dose of methadone supplemented by propoxyphene napsylate)
Number of subjects: 22
Study: 31096538

Group type: EXPERIMENTAL
Intervention: Single-dose rectal indomethacin administration
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Double-dose rectal indomethacin administration
Number of subjects: 162

Group type: COMPARATOR
Intervention: Difficult cannulation as a risk factor
Number of subjects: 162
Study: 26884344

Group type: EXPERIMENTAL
Intervention: S-1 (tegafur, gimeracil, and oteracil)
Number of subjects: 829
Study: 25552396

Group type: EXPERIMENTAL
Intervention: Sonoma CRx intramedullary pin (IMP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Minimally invasive locking midshaft superior plating (MIPPO)
Number of subjects: 45
Study: 24362706

Group type: EXPERIMENTAL
Intervention: CocoaCHOC: 350 mg flavanols per serving
Number of subjects: 8

Group type: COMPARATOR
Intervention: CHOC: 0 mg flavanols
Number of subjects: 8
Study: 20352525

Group type: EXPERIMENTAL
Intervention: Bioenterics intragastric balloon (BIB)
Number of subjects: 33
Study: 18986657

Group type: EXPERIMENTAL
Intervention: Hamilton depression rating scale (HAMD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montgomery‐Asberg depression rating scale (MADRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hamilton anxiety rating scale (HAMA)
Number of subjects: 0
Study: 17021748

Group type: EXPERIMENTAL
Intervention: Stapled transanal rectal resection (STARR)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Stapled anopexy (SA)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: STARR
Number of subjects: 68

Group type: COMPARATOR
Intervention: SA
Number of subjects: 68
Study: 15136218

Group type: EXPERIMENTAL
Intervention: Thalidomide treatment
Number of subjects: 34
Study: 11318759

Group type: EXPERIMENTAL
Intervention: BioMedicus centrifugal pump
Number of subjects: 1000

Group type: COMPARATOR
Intervention: roller pump
Number of subjects: 1000
Study: 9454350

Group type: EXPERIMENTAL
Intervention: CHARTWEEL radiotherapy to 60 Gy (15 weekly fractions of 1.5 Gy)
Number of subjects: 665

Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy to 66 Gy (5 weekly fractions of 2 Gy)
Number of subjects: 665
Study: 8094114

Group type: EXPERIMENTAL
Intervention: Gentamicin 4 mg/kg once daily (OD)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Gentamicin 1.33 mg/kg three times daily (MD)
Number of subjects: 123
Study: 3679647

Group type: EXPERIMENTAL
Intervention: Electrical stimulation with low frequency (50 Hz) for 21 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Electrical stimulation with high frequency (2000 Hz) for 21 days
Number of subjects: 22
Study: 31856887

Group type: EXPERIMENTAL
Intervention: Twice-daily nebulised hypertonic saline (HTS 6%) with standard care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbocisteine (750 mg three times per day until visit 3, reducing to 750 mg twice per day) with standard care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of twice-daily nebulised HTS and carbocisteine with standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 29373476

Group type: EXPERIMENTAL
Intervention: MEDI8897 50 mg
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: MEDI8897
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 26395174

Group type: EXPERIMENTAL
Intervention: OLM/AML 40/10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: PER/AML 8/10 mg
Number of subjects: 0
Study: 25421512

Group type: EXPERIMENTAL
Intervention: naltrexone
Number of subjects: 64

Group type: COMPARATOR
Intervention: acamprosate
Number of subjects: 64
Study: 23025349

Group type: EXPERIMENTAL
Intervention: Prolonged-release oxycodone/naloxone (OXN PR) tablets (20/10 mg) with slow, medium, and fast dissolution rates.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged-release oxycodone/naloxone (OXN PR) tablets (20/10 mg) with varying dissolution rates.
Number of subjects: 0
Study: 20595477

Group type: EXPERIMENTAL
Intervention: IV-ibuprofen 400 mg every 6 hours for 72 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo every 6 hours for 72 hours
Number of subjects: 60
Study: 18538997

Group type: EXPERIMENTAL
Intervention: Telephone survey
Number of subjects: 720

Group type: COMPARATOR
Intervention: Mail survey
Number of subjects: 720
Study: 15833505

Group type: EXPERIMENTAL
Intervention: Spanish version of the PUF questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spanish version of the PUF questionnaire (retest)
Number of subjects: 0

Group type: COMPARATOR
Intervention: English version of the PUF questionnaire
Number of subjects: 0
Study: 12927659

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 18
Study: 10685829

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfasalazine (SASP)
Number of subjects: 0
Study: 8863236

Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH, 0.2 mg/kg/d)
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study: 1321655

Group type: EXPERIMENTAL
Intervention: Flunarizine 10 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 6547612

Group type: EXPERIMENTAL
Intervention: Intrathecal cinchocaine with morphine hydrochloride 2.5 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intrathecal cinchocaine alone
Number of subjects: 20
Study: 3453169

Group type: EXPERIMENTAL
Intervention: Stepped care (SC) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Referred care (RC) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure (SBP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline diastolic blood pressure (DBP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postrandomization reduction in SBP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced DBP
Number of subjects: 0
Study: 29251700

Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH) 30 mg BID
Number of subjects: 150

Group type: COMPARATOR
Intervention: Aspirin 81 mg BID
Number of subjects: 150
Study: 27708113

Group type: EXPERIMENTAL
Intervention: Single session quit advice (15 min) plus a single training session in yogic breathing exercises
Number of subjects: 1213

Group type: COMPARATOR
Intervention: Very brief quit advice (1 min) alone
Number of subjects: 1213
Study: 26246907

Group type: EXPERIMENTAL
Intervention: vBloc
Number of subjects: 239

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 239
Study: 23913744

Group type: EXPERIMENTAL
Intervention: Prior ketoconazole therapy
Number of subjects: 1050
Study: 21939418

Group type: EXPERIMENTAL
Intervention: Once-weekly recombinant factor VIII prophylaxis, with up to two rescue doses per week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrice-weekly prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interdose thrombin generation assessment
Number of subjects: 0
Study: 19050582

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 222

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 222
Study: 16284230

Group type: EXPERIMENTAL
Intervention: Young subjects
Number of subjects: 40

Group type: COMPARATOR
Intervention: Elderly sedentary subjects
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Elderly fit subjects
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lifelong exercise training
Number of subjects: 40
Study: 11991797

Group type: EXPERIMENTAL
Intervention: Lower extremities (LEs) rehabilitation
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Upper extremities (UEs) rehabilitation
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control treatment (paretic arm and leg immobilized)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Walking speed increase
Number of subjects: 53
Study: 9808909

Group type: EXPERIMENTAL
Intervention: Regular haemodialysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 7655779

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention group
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 127
Study: 2655259

Group type: EXPERIMENTAL
Intervention: Short-term intravesical therapy (STIT) with 1% solution of Epodyl, given once per week for 6 weeks
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Long-term intravesical therapy (LTIT) with 1% solution of Epodyl, consisting of STIT followed by an additional dose once a month for 2 years
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Short-term intravesical therapy (STIT) for solitary tumors
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Long-term intravesical therapy (LTIT) for solitary tumors
Number of subjects: 114
Study: 875786

Group type: EXPERIMENTAL
Intervention: Viloxazine (100 mg three times a day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Imipramine (50 mg three times a day)
Number of subjects: 22
Study: 30169969

Group type: EXPERIMENTAL
Intervention: ATTRm amyloidosis patients
Number of subjects: 172
Study: 25812725

Group type: EXPERIMENTAL
Intervention: Acupuncture at local points (JOI‐LP)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Acupuncture at distant points (MUS‐DP)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Acupuncture at local points (MUS‐LP)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Acupuncture at distant points (JOI‐DP)
Number of subjects: 68
Study: 24092822

Group type: EXPERIMENTAL
Intervention: Function‐Focused Care for the Cognitively Impaired Intervention
Number of subjects: 103
Study: 22851700

Group type: EXPERIMENTAL
Intervention: Very Low Frequency Power (VLFP)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Low Frequency Power (LFP)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Turbulence Slope (TS)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Impaired Turbulence Slope (<2.5 ms per RR interval)
Number of subjects: 388
Study: 20525780

Group type: EXPERIMENTAL
Intervention: 4-mg nicotine lozenge with behavioral intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Behavioral intervention alone
Number of subjects: 102
Study: 18427418

Group type: EXPERIMENTAL
Intervention: Vitamin C (VC: 1 000 mg vitamin C)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 16153930

Group type: EXPERIMENTAL
Intervention: Aspirin (150 mg orally 12 and 3 hours before surgery)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 14648739

Group type: EXPERIMENTAL
Intervention: Lateral pelvic lymph node dissection (LPLD)
Number of subjects: 246

Group type: COMPARATOR
Intervention: No lateral pelvic lymph node dissection (No LPLD)
Number of subjects: 246
Study: 10613576

Group type: EXPERIMENTAL
Intervention: Levodopa 5, 10, or 20 mg (for children <40 kg) or 10, 20, or 40 mg (for children ≥40 kg) 3 times a day
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa combination
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 7562679

Group type: EXPERIMENTAL
Intervention: Standardized sodium diet with water loading (2290 ml in 3 1/2 hr) and competitive videogame stress test
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg b.i.d.
Number of subjects: 48
Study: 1975484

Group type: EXPERIMENTAL
Intervention: Neostigmine (70 micrograms/kg) with glycopyrrolate (15 micrograms/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 40
Study: 7384332

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Amitriptyline and Diazepam
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 29476913

Group type: EXPERIMENTAL
Intervention: Stress induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 0
Study: 27801407

Group type: EXPERIMENTAL
Intervention: Intravascular laser irradiation of blood (daily 25 min sessions for 7 days, 2 MW, 0.63 microns)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pharmacotherapy alone (control group)
Number of subjects: 30
Study: 25080458

Group type: EXPERIMENTAL
Intervention: Intermittent lack-of-adherence model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metabolic adaptation model
Number of subjects: 0
Study: 22635125

Group type: EXPERIMENTAL
Intervention: Metacognitive intervention program based on social mediation, cooperative learning, and metacognition (3 months duration)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 29
Study: 20552094

Group type: EXPERIMENTAL
Intervention: Chlorinated polyethylene elastomer (CPE) prosthesis
Number of subjects: 42

Group type: COMPARATOR
Intervention: Silicone elastomer prosthesis
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Chlorinated polyethylene elastomer (CPE) prosthesis for new users
Number of subjects: 42

Group type: COMPARATOR
Intervention: Silicone elastomer prosthesis for new users
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Chlorinated polyethylene elastomer (CPE) prosthesis for previous users
Number of subjects: 42

Group type: COMPARATOR
Intervention: Silicone elastomer prosthesis for previous users
Number of subjects: 42
Study: 19089285

Group type: EXPERIMENTAL
Intervention: Chloroform
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Orange oil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Eucalyptol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 16111588

Group type: EXPERIMENTAL
Intervention: Central lymphatic irradiation (CLI)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Alternating triple therapy (ATT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both CLI and ATT
Number of subjects: 65
Study: 12022436

Group type: EXPERIMENTAL
Intervention: RRV-TV (4 x 10(4) pfu/dose)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 540
Study: 10819233

Group type: EXPERIMENTAL
Intervention: Erythromycin 400 mg orally three times a day for 1 week
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Erythromycin 200 mg orally three times a day for 4 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intravenous erythromycin 10 mg x kg(‐1) x h(‐1)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 8991774

Group type: EXPERIMENTAL
Intervention: Nerve not identified intraoperatively (Group I)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Nerve identified intraoperatively (Group II)
Number of subjects: 800
Study: 7038165

Group type: EXPERIMENTAL
Intervention: 1 g of sulfisoxazole
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 2 g of sulfisoxazole
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: trimethoprim 160 mg and sulfamethoxazole 800 mg
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: trimethoprim 320 mg and sulfamethoxazole 1,600 mg
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 117
Study: 31610021

Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA) 15 mg once daily (q.d.)
Number of subjects: 3685

Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA) 30 mg once daily (q.d.)
Number of subjects: 3685

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 3685

Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA)
Number of subjects: 3685
Study: 31319590

Group type: EXPERIMENTAL
Intervention: Cod protein hydrolysate (CPH) 2.5 g daily for 6 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (CPH and placebo)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Baseline measures for the whole group
Number of subjects: 28
Study: 27717236

Group type: EXPERIMENTAL
Intervention: Vitamin D3 28,000 IU once weekly for 24 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 25885668

Group type: EXPERIMENTAL
Intervention: Home-based inspiratory muscle training (IMT) programme at intensity >30% maximum inspiratory pressure (PImax) for 7 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group with training at intensity <15% PImax for 7 weeks
Number of subjects: 68
Study: 24522786

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention involving multidisciplinary care, education, and regular monitoring
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention
Number of subjects: 60
Study: 22949149

Group type: EXPERIMENTAL
Intervention: High-dose (≥ 30 Gy) thoracic radiation (n = 38)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Lower-dose (< 30 Gy) thoracic radiation combined with anthracycline (n = 24)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Higher thoracic radiation dose
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Survivors with leukoencephalopathy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Working memory impairment
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Neurocognitive performance
Number of subjects: 62
Study: 20589590

Group type: EXPERIMENTAL
Intervention: Vibration Group (n=12, static and dynamic exercises on a vibration plate, frequency: 15-25 Hz, amplitude: 2-12.8 cm)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Strength Group (n=16, same exercises without vibration)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control Group (n=10)
Number of subjects: 38
Study: 17606723

Group type: EXPERIMENTAL
Intervention: i.p. catumaxomab (5 to 200 microg)
Number of subjects: 23
Study: 15749317

Group type: EXPERIMENTAL
Intervention: Cefuroxime administered intravascularly as a bolus dose of 1.5 g
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 17
Study: 12218843

Group type: EXPERIMENTAL
Intervention: Intervention (Project SAFE)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Control
Number of subjects: 249